辉瑞公司在第三季度业绩超预期后上调了全年业绩展望，因为其新型药物需求增长帮助这家制药商抵消了新冠产品销售下滑的影响。
Inc. raised its full-year outlook after it outperformed in the third quarter, as growing demand for its newer medicines helped the drugmaker offset declining sales of its Covid products.
该制药商现在预计全年营收将达到620亿美元至640亿美元，调整后每股收益为2.95美元至3.05美元。此前预测营收为605亿美元至625亿美元，调整后每股收益为2.80美元至3美元。这家总部位于纽约的制药商报告的第三季度利润和销售均好于预期。它是第三季度期间超越华尔街预期的最新一家制药公司。上周，礼来公司、默克公司和百时美施贵宝公司均在提高年度预测的公司之列。
The drugmaker now expects full-year revenue of $62 billion to $64 billion and adjusted earnings of $2.95 to $3.05 a share. It previously forecast revenue of $60.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a The New York-based drugmaker reported better-than-anticipated third-quarter profit and sales. It’s the latest pharma company to surpass Wall Street expectations during the period. Last week, Eli Lilly & Co., Merck & Co. and Bristol Myers Squibb Co. were all among companies that raised their annual forecast.
周二纽约早盘交易中，股价上涨不到1%。截至周一收盘，今年以来股价已累计上涨23%。
Shares rose less than 1% in early trading in New York on Tuesday. They’ve gained 23% so far this year, through Monday’s close.
辉瑞正试图在获得巨大疫情红利后重塑自我。首席执行官Albert Bourla转向并购、新型癌症药物以及在肥胖症治疗领域的雄心勃勃的布局，以在新冠销售消退、公司一些畅销药面临更便宜替代品竞争的情况下重振增长。
Pfizer is trying to reinvent itself after a major pandemic windfall. Chief Executive Officer Albert Bourla has turned to acquisitions, new cancer medicines and an ambitious push into obesity treatments to revive growth as Covid sales fade and some of the company’s biggest drugs face competition from cheaper alternatives.
肥胖症领域是辉瑞的重大押注之一，公司正寻求向市场领导者礼来公司和诺和诺德发起挑战。辉瑞去年收购了Metsera Inc.，获得了包括一种设计为每月注射一次而非每周一次的实验性疗法在内的多项实验性疗法。公司目前正在推进广泛的临床项目，以测试其药物能否在快速扩张的市场中具有竞争力。
One of Pfizer’s major bets is in obesity, where it is seeking to challenge market leaders Eli Lilly & Co. and Novo Nordisk A/S. Pfizer bought Metsera Inc. last year, gaining experimental treatments including a shot designed to be taken once a month rather than weekly. The company is now advancing an extensive clinical program to test whether its medicines can compete in the rapidly expanding market.
癌症是另一个重点领域。辉瑞斥资430亿美元收购Seagen，获得了一系列癌症药物，包括治疗膀胱癌的药物Padcev。该药物第三季度销售超预期。
Cancer is another major focus. Pfizer’s $43 billion acquisition of Seagen gave it a portfolio of cancer medicines, including Padcev, a treatment for bladder cancer. Sales of that drug beat estimates in the third quarter.
心脏药物 Vyndaqel 销售额为 17.7 亿美元，略高于预期。肺炎球菌疫苗 Prevnar 收入为 15.6 亿美元，而抗凝血药 Eliquis 本季度带来 25.2 亿美元收入。
Sales of heart drug Vyndaqel were $1.77 billion, slightly higher than estimates. Revenues from pneumococcal vaccine Prevnar were $1.56 billion while the blood thinner Eliquis brought in $2.52 billion in the quarter.
辉瑞还在通过激进的成本削减来提高盈利能力。另外，公司周二表示，临时首席财务官 Cecile Guegan 将正式担任该职务。
Pfizer is also seeking to improve profitability through aggressive cost cutting. Separately, the company said Tuesday interim Chief Financial Officer Cecile Guegan would take on the role permanently.